Carbidopa
Brand Names: Lodosyn
Methodology & AI Transparency ⓘ
Carbidopa Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.
- 2 Real-world patient consensus: Tracked across 11 patient dosage logs with a 79% satisfaction benchmark (RxCUI 260260).
- 3 Typical cash cost range: Dispensing cost comparison spans $13.63 mail/discount cash up to $35.63 uninsured retail (federal NADAC $0.5325).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Carbidopa): nausea (10.4%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Carbidopa
Carbidopa Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa tablets are for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.
CLINICAL PHARMACOLOGY Parkinson’s disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility. Mechanism of Action Current evidence indicates that symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum.
Pharmacokinetic profiling of Carbidopa demonstrates an elimination half-life of Biphasic clearance with 8–15 hr terminal t½ under Carbidopa maintenance with Systemic oral bioavailability of roughly 50%–62% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (carbidopa), reaching clinical onset within initial pharmacodynamic onset within 1–3 hrs (peak cmax) for carbidopa.
Titration schedules for Carbidopa (25 mg/1 Tablet → 25mg Tablet) require excluding contraindications carbidopa tablets are contraindicated in patients with known hypersensitivity to any component of this drug.; nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa.; real-world patient logs highlight nausea (10.4% of reports), headache (7.1% of reports), dizziness (6.2% of reports) alongside a 79.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Carbidopa (aromatic amino acid decarboxylation inhibitor).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Carbidopa dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Carbidopa tablets are contraindicated in patients with known hypersensitivity to any component of this drug.
- Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa.
Logged Side-Effect Incidence (11 Reports)
Carbidopa Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Carbidopa)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Controlled trial evaluating synbiotic supplementation as an add-on treatment in Supplementing with synbiotics exhibits promising neuroprotective and therapeutic effects in the treatment of Parkinson's disease patients. Inflammopharmacology • 2025-07-15 • Phase III Randomized Trial | N = 33 | 82/100 | PMID 40434674 ↗ |
| Can This Approach Help? Inside the Latest Research on Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time. Movement disorders clinical practice • 2024-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38465885 ↗ |
| Can This Approach Help? Inside the Latest Research on Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a LCIG significantly reduced dyskinesia compared with OMT. Movement disorders : official journal of the Movement Disorder Society • 2021-11-15 • Phase III Randomized Trial | N = 30 | 82/100 | PMID 34236101 ↗ |
Carbidopa Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5325/unit (~$15.97/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $13.63 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $35.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $15.67 / mo | View logs ↓ |
Carbidopa Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Carbidopa RxNorm Concept ID | 260260 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5325 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $35.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $13.63 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Carbidopa Patient Community, Cohort Filters & Dosage Logs
Deterministic Carbidopa reference combining NIH RxNorm (260260), Medicaid NADAC ($0.5325/unit), and anonymous cohort outcomes (79% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Carbidopa community threads and patient logs by age, biological sex, dosage, and treatment duration.